Quick Answer
Acurx Pharmaceuticals, Inc. reported Stockholders Equity of $5.27 million for fiscal year 2025.
Acurx Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.27M | +756.5% |
| 2024 | $615.1K | -86.8% |
| 2023 | $4.67M | -36.2% |
| 2022 | $7.32M | -41.1% |
| 2021 | $12.41M | +359.4% |
| 2020 | $2.70M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.64M | +36.5% | +2.0% |
| June 30, 2025 | $3.57M | +4.1% | +54.3% |
| March 31, 2025 | $2.31M | -61.5% | +275.8% |
| December 31, 2024 | $615.1K | -86.8% | -76.9% |
| September 30, 2024 | $2.66M | -32.3% | -22.3% |
| June 30, 2024 | $3.43M | -44.9% | -42.9% |
| March 31, 2024 | $6.00M | +12.9% | +28.5% |
| December 31, 2023 | $4.67M | -36.2% | +18.6% |
- Acurx Pharmaceuticals, Inc. showed an increase of +756.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Acurx Pharmaceuticals, Inc.’s stockholders equity has grown by 95.0% (from $2.70 million to $5.27 million).
- The most recent figure is from Acurx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: